Kishor Vora, MD
Cardiovascular Disease · Owensboro, KYNPI 1992753727
Payments from drug & device makers
Across 926 payments — averaging $4847.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1M
- AstraZeneca$840K
- Astrazeneca UK Limited$642K
- Novartis$596K
- Romark Laboratories, LC$557K
- AbbVie$338K
- plus $482K from 47 others
What the payments were for
- Consulting fees$1,6008%
- Speaking & faculty fees$10,60050%
- Travel & lodging$3,97319%
- Food & beverage$4,86323%
- Education$1971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$10,600
- POD$1,956
- Selectra$837
- Quadra Assura CRT Defibrillator$800
- Endurity Pacemaker$800
- Solia$725
- PANTHERIS$654
- Peripheral Orbital Atherectomy System$425
- Micra$369
- INTERVENTIONAL ANGIOGRAPHY SYSTEM$305
- Indigo$222
- Penumbra System$172
- GENERAL VASCULAR INTERVENTION$113
- Supera peripheral stent system$107
How this compares
$4,488,663 in reported general payments places this provider in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 924 | $877,566 |
| EntrestoSacubitril/Valsartan | 682 | $842,228 |
| FarxigaDapagliflozin Propanediol | 410 | $401,747 |
| XareltoRivaroxaban | 177 | $164,402 |
| Repatha SureclickEvolocumab | 127 | $103,135 |
| JardianceEmpagliflozin | 69 | $69,510 |
| Ranolazine ErRanolazine | 729 | $63,453 |
| BrilintaTicagrelor | 78 | $61,150 |
| Potassium Chloride | 1,327 | $24,575 |
| ClopidogrelClopidogrel Bisulfate | 2,649 | $24,027 |
| Praluent PenAlirocumab | 32 | $18,752 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 1,911 | $18,734 |
| Atorvastatin Calcium | 1,685 | $13,316 |
| Prasugrel Hcl | 114 | $12,123 |
| Metoprolol Succinate | 1,125 | $11,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $40 | $877,566924 claims |
| NovartisEntresto | $596,490 | $842,228682 claims |
| AstraZenecaFarxiga, Brilinta | $839,606 | $462,898488 claims |
| Johnson & JohnsonXarelto | $235 | $164,402177 claims |
| Boehringer IngelheimJardiance | $1,033,459 | $69,51069 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $125 | $9,18811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Owensboro
- Madhura MylaOwensboro$58K
- Dinesh KalraLouisville$739K
- Amir PirachaLouisville$590K
- Rohan SamsonLouisville$527K
- Shahab GhafghaziLouisville$404K
- William SkinnerLexington$346K
- Vipul PanchalLouisville$301K
- John KotterLexington$241K
- John HarrisLouisville$226K
- Suresh SharmaLexington$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.